Damulin B

CAS No. 1202868-75-4

Damulin B( —— )

Catalog No. M32154 CAS No. 1202868-75-4

Damulin B is a natural product for research related to life sciences.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
10MG 495 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Damulin B
  • Note
    Research use only, not for human use.
  • Brief Description
    Damulin B is a natural product for research related to life sciences.
  • Description
    Damulin B is a natural product for research related to life sciences.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1202868-75-4
  • Formula Weight
    783
  • Molecular Formula
    C42H70O13
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : ≥ 50 mg/mL (63.86 mM)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 1-Phenyloctane

    1-Phenyloctane enhances the liquid-phase exfoliation of graphene in organic solvents.

  • Diclofenac Epolamine

    Diclofenac Epolamine is a non-steroidal anti-inflammatory agent (NSAID) with analgesic and antipyretic actions.

  • Syk Inhibitor II hyd...

    The impact of spleen tyrosine kinase (Syk) signaling might be prominent in lupus because (i) Syk is a shared downstream signaling molecule among circulating immune complex, LPS, and (1→3)-β-D-glucan (BG), and (ii) all of these factors are detectable in the serum of Fc gamma receptor IIb-deficient (FcgRIIb-/-) mice with sepsis. Syk inhibition downregulated several inflammatory pathways in FcgRIIb-/- macrophages activated with BG + LPS suggesting the potential anti-inflammatory impact of Syk inhibitors in lupus.